GlassScriptPhysician profile
Scott G Petrie
NPI 1700802733
$8,078.70
in general payments reported to CMS, 2019-2025
34 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $983 · 2021: $987 · 2022: $779 · 2023: $854 · 2024: $1,225 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,390.61 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Radius Health, INC. | $1,258.12 | 2019-2025 | Tymlos |
| Forte Bio-Pharma LLC | $1,113.21 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Alon Medical Technology | $906.00 | 2019 | |
| Horizon Therapeutics Plc | $599.78 | 2019-2022 | |
| Pacira Therapeutics, INC. | $484.16 | 2019-2021 | |
| Stryker Corporation | $394.70 | 2019-2025 | Mako, Variax, Hydroset |
| Valinor Pharma, LLC | $280.97 | 2024-2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $216.70 | 2019-2022 | |
| Zynex Medical, INC. | $168.56 | 2025 | Nexwave |
| Pacira Pharmaceuticals Incorporated | $150.31 | 2020-2025 | Zilretta, Iovera, Exparel |
| Azurity Pharmaceuticals, INC. | $131.27 | 2023-2024 | Horizant, Horizant |
| Depuy Synthes Sales INC. | $112.52 | 2019-2025 | Monovisc |
| Vertex Pharmaceuticals Incorporated | $88.02 | 2024-2025 | |
| Virtus Pharmaceuticals LLC | $84.33 | 2024-2025 | Levorphanol Tartrate |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $76.16 | 2019-2024 | Durolane, Exogen Ultrasound Bone Healing System |
| Kowa Pharmaceuticals America, INC. | $75.17 | 2022 | |
| Fidia Pharma USA INC. | $72.57 | 2021-2024 | Hyalgan, Hymovis, Triluron |
| Astrazeneca Pharmaceuticals LP | $53.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.99 | 2024-2025 | Relistor |
| Dynasplint Systems INC. | $45.93 | 2025 | Dynasplint |
| Ferring Pharmaceuticals INC. | $43.26 | 2019-2020 | |
| Vericel Corporation | $42.50 | 2021-2023 | Maci |
| Sanofi-Aventis U.S. LLC | $37.82 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $37.49 | 2019 | |
| Fujifilm Sonosite, INC. | $30.00 | 2019 | |
| Orthalign INC | $29.31 | 2023 | Orthalign Plus |
| Ethicon US, LLC | $24.73 | 2019 | |
| Davol INC. | $22.72 | 2023 | Arista Ah Flexitip |
| Pfizer INC. | $14.79 | 2019 | |
| Avanos Medical | $14.44 | 2022 | |
| Shionogi INC | $12.04 | 2019 | |
| Kerecis Limited | $10.62 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Musculoskeletal Transplant Foundation INC. | $5.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Petrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.